scholarly journals Physiology and Pathology of Infectious Diseases: The Autoimmune Hypothesis of Chagas Disease

2017 ◽  
Author(s):  
Armanda Moreira Mattoso-Barbosa ◽  
Renato Sathler-Avelar ◽  
Jordana Grazziela Alves Coelho-dos-Reis ◽  
Olindo Assis Martins-Filho ◽  
Andrea Teixeira-Carvalho ◽  
...  
Keyword(s):  
Infectious Diseases ◽  
Chagas Disease

scholarly journals New drugs for neglected infectious diseases: Chagas' disease

2010 ◽  
Vol 160 (2) ◽  
pp. 258-259 ◽  
Author(s):  
Fabiana S Machado ◽  
Herbert B Tanowitz ◽  
Mauro M Teixeira
Keyword(s):  
Infectious Diseases ◽  
Chagas Disease ◽  
New Drugs

scholarly journals An Overview on the Therapeutics of Neglected Infectious Diseases—Leishmaniasis and Chagas Diseases

2021 ◽  
Vol 9 ◽  
Author(s):  
Brindha J ◽  
Balamurali M. M ◽  
Kaushik Chanda
Keyword(s):  
Infectious Diseases ◽  
Chagas Disease ◽  
Biosynthetic Pathway ◽  
Neglected Tropical Diseases ◽  
Nucleoside Analogs ◽  
Severe Toxicity ◽  
Drug Candidates ◽  
Chemical Structures ◽  
The Past ◽  
Associated Proteins

Neglected tropical diseases (NTDs) as termed by WHO include twenty different infectious diseases that are caused by bacteria, viruses, and parasites. Among these NTDs, Chagas disease and leishmaniasis are reported to cause high mortality in humans and are further associated with the limitations of existing drugs like severe toxicity and drug resistance. The above hitches have rendered researchers to focus on developing alternatives and novel therapeutics for the treatment of these diseases. In the past decade, several target-based drugs have emerged, which focus on specific biochemical pathways of the causative parasites. For leishmaniasis, the targets such as nucleoside analogs, inhibitors targeting nucleoside phosphate kinases of the parasite’s purine salvage pathway, 20S proteasome of Leishmania, mitochondria, and the associated proteins are reviewed along with the chemical structures of potential drug candidates. Similarly, in case of therapeutics for Chagas disease, several target-based drug candidates targeting sterol biosynthetic pathway (C14-ademethylase), L-cysteine protease, heme peroxidation, mitochondria, farnesyl pyrophosphate, etc., which are vital and unique to the causative parasite are discussed. Moreover, the use of nano-based formulations towards the therapeutics of the above diseases is also discussed.

scholarly journals Anti-trypanosomal screening of Salvadoran flora

2021 ◽  
Author(s):  
Ulises G. Castillo ◽  
Ayato Komatsu ◽  
Morena L. Martínez ◽  
Jenny Menjívar ◽  
Marvin J. Núñez ◽  
...  
Keyword(s):  
Infectious Diseases ◽  
Trypanosoma Cruzi ◽  
Central America ◽  
Chagas Disease ◽  
Literature Search ◽  
Methanolic Extract ◽  
Protozoan Parasite ◽  
Methanolic Extracts ◽  
Aerial Parts ◽  
Historia Natural

AbstractChagas disease is caused by the protozoan parasite Trypanosoma cruzi, and in Central America, it is considered one of the four most infectious diseases. This study aimed to screen the anti-trypanosomal activity of plant species from Salvadoran flora. Plants were selected through literature search for plants ethnobotanically used for antiparasitic and Chagas disease symptomatology, and reported in Museo de Historia Natural de El Salvador (MUHNES) database. T. cruzi was incubated for 72 h with 2 different concentrations of methanolic extracts of 38 species, among which four species, Piper jacquemontianum, Piper lacunosum, Trichilia havanensis, and Peperomia pseudopereskiifolia, showed the activity (≤ 52.0% viability) at 100 µg/mL. Separation of the methanolic extract of aerial parts from Piper jacquemontianum afforded a new flavanone (4) and four known compounds, 2,2-dimethyl-6-carboxymethoxychroman-4-one (1), 2,2-dimethyl-6-carboxychroman-4-one (2), cardamomin (3), and pinocembrin (5), among which cardamomin exhibited the highest anti-trypanosomal activity (IC50 = 66 µM). Detailed analyses of the spectral data revealed that the new compound 4, named as jaqueflavanone A, was a derivative of pinocembrin having a prenylated benzoate moiety at the 8-position of the A ring. Graphic abstract

Insight into Recent Drug Discoveries against Trypanosomatids and Plasmodium spp Parasites: New Metal-based Compounds

2021 ◽  
Vol 28 ◽  
Author(s):  
Cauê Benito Scarim ◽  
Renan Lira de Farias ◽  
Diego Eidy Chiba ◽  
Chung Man Chin
Keyword(s):  
Inorganic Chemistry ◽  
Drug Discovery ◽  
Infectious Diseases ◽  
Chagas Disease ◽  
Human African Trypanosomiasis ◽  
Review Article ◽  
Pharmacological Activities ◽  
Tropical Infectious Diseases ◽  
Medicinal Inorganic Chemistry ◽  
Insight Into

: Scaffolds of metal-based compounds can act as pharmacophore groups in several ligands to treat various diseases, including tropical infectious diseases (TID). In this review article, we investigate the contribution of these moieties to medicinal inorganic chemistry in the last seven years against TID, including American trypanosomiasis (Chagas disease), human African trypanosomiasis (HAT, sleeping sickness), leishmania, and malaria. The most potent metal-based complexes are displayed and highlighted in figures, tables and graphics; according to their pharmacological activities (IC50 > 10µM) against Trypanosomatids and Plasmodium spp parasites. We highlight the current progresses and viewpoints of these metal-based complexes, with a specific focus on drug discovery.

Survey of Pediatric Infectious Diseases Society Members About Congenital Chagas Disease

2018 ◽  
Vol 37 (1) ◽  
pp. e24-e27 ◽  
Author(s):  
Morven S. Edwards ◽  
Francisca A. Abanyie ◽  
Susan P. Montgomery
Keyword(s):  
Infectious Diseases ◽  
Chagas Disease

scholarly journals Trypanosoma cruzi I genotype among isolates from patients with chronic Chagas disease followed at the Evandro Chagas National Institute of Infectious Diseases (FIOCRUZ, Brazil)

2017 ◽  
Vol 50 (1) ◽  
pp. 35-43 ◽  
Author(s):  
Tatiana da Silva Fonseca de Oliveira ◽  
Barbara Neves dos Santos ◽  
Tainah Silva Galdino ◽  
Alejandro Marcel Hasslocher-Moreno ◽  
Otilio Machado Pereira Bastos ◽  
...  
Keyword(s):  
Infectious Diseases ◽  
Trypanosoma Cruzi ◽  
Chagas Disease ◽  
Chronic Chagas Disease

The medicinal chemistry of 3-nitro-1,2,4-triazoles: focus on infectious diseases

2021 ◽  
Vol 21 ◽  
Author(s):  
Rodolfo Rodrigo Florido França ◽  
Cheyene Almeida Celestino Menozzi ◽  
Frederico Silva Castelo-Branco ◽  
Lucas Villas Bôas Hoelz ◽  
Nubia Boechat
Keyword(s):  
Infectious Diseases ◽  
Chagas Disease ◽  
Medicinal Chemistry ◽  
Fungal Infections ◽  
Pathogenic Fungi ◽  
Sleeping Sickness ◽  
New Drugs ◽  
Cross Resistance ◽  
Ergosterol Biosynthesis ◽  
Etiological Agents

: Infectious diseases are among the leading causes of death worldwide, especially in developing countries. The historical lack of interest of the pharmaceutical industry in developing new drugs against many of these diseases, such as tuberculosis, leishmaniasis, Chagas disease, sleeping sickness, and fungal infections, has left millions of individuals dependent on old treatments that are often ineffective and present different adverse effects. In this sense, new substances against these diseases must be identified. A class of substances that has stood out in the search for new drugs against these diseases is azole derivatives. Within this class, the 3-nitro-1,2,4-triazole nucleus has attracted increasing interest due to its potential, specifically when compared to the 1,2,4-triazole nucleus without the presence of the nitro group, and also in relation to the 2-nitroimidazole nucleus, showing greater potency and selectivity against different etiological agents. This is even more relevant considering that 3-nitro-1,2,4-triazolic substances can promote their activity through different mechanisms of action, such as the inhibition of ergosterol biosynthesis and also via activation by the nitroreductase enzyme, which can avoid the development of cross-resistance. Therefore, in this review, the medicinal chemistry of nitrotriazoles is discussed through the analysis of their potential in terms of biological activity against the etiological agents of several diseases, such as Chagas disease, sleeping sickness and leishmaniasis, caused by kinetoplastid parasites, tuberculosis, caused by the mycobacteria Mycobacterium tuberculosis, and against different species of pathogenic fungi. In addition, aspects related to enzymatic activities, molecular modeling and organic synthesis of these substances are also addressed.

Heterocyclic N-oxides - A Promising Class of Agents against Tuberculosis, Malaria and Neglected Tropical Diseases

2018 ◽  
Vol 24 (12) ◽  
pp. 1325-1340 ◽  
Author(s):  
Guilherme Felipe dos Santos Fernandes ◽  
Aline Renata Pavan ◽  
Jean Leandro dos Santos
Keyword(s):  
Infectious Diseases ◽  
Chagas Disease ◽  
Medicinal Chemistry ◽  
Neglected Tropical Diseases ◽  
Biologically Active ◽  
Tropical Diseases ◽  
Pharmacological Effects

Heterocyclic N-oxides have emerged as promising agents against a number of diseases and disorders, especially infectious diseases. This review analyzes the emergence and development of this scaffold in the medicinal chemistry, focusing mainly on the discovery of new heterocyclic N-oxide compounds with potent activity against tuberculosis, malaria and neglected tropical diseases (i.e. leishmaniasis and Chagas disease). A number of heterocyclic N-oxides are described herein, nevertheless, the following chemical classes deserve to be highlighted due to a large number of reports in the literature about their promising pharmacological effects: furoxan, benzofuroxan, quinoxaline 1,4-di-N-oxide, indolone N-oxide and benzimidazole N-oxide. In order to describe those most promising compounds, we included in this review only those most biologically active heterocyclic Noxide published since 2000.

scholarly journals Chronic Care for Neglected Infectious Diseases: Leprosy/Hansen's Disease, Lymphatic Filariasis, Trachoma, and Chagas Disease

2021 ◽  
Keyword(s):  
Health Care ◽  
Primary Health Care ◽  
Infectious Diseases ◽  
Lymphatic Filariasis ◽  
Chagas Disease ◽  
Chronic Conditions ◽  
Disability Prevention ◽  
Care Level ◽  
Primary Health ◽  
Primary Health Care Level

In 2016, PAHO's Directing Council, through Resolution CD55.R9, approved the “Plan of Action for Elimination of Neglected Infectious Diseases (NID) and Post-Elimination Actions, 2016-2022.” This Resolution urges Member States to implement a set of interventions to reduce the burden of disease by NID in the Americas by 2022, including  “…support promotion of treatment, rehabilitation, and related support services through an approach focused on integrated morbidity management and disability prevention for individuals and families afflicted by those neglected infectious diseases that cause disability and generate stigma.” NIDs can have devastating chronic sequelae for patients, such as disability, visible change or loss in body structure, loss of tissue, and impairment of proper tissue and organ function, among others. All of these can in turn lead to unjustified discrimination, stigmatization, mental health problems, and partial or total incapacity to work, perpetuating the vicious cycle of neglected diseases as both a consequence and a cause of poverty. Patients with chronic conditions caused by NIDs require proper health care in order to prevent further damage and improve their living and social conditions. This should be provided at the primary health care level, as patients suffering from NIDs are often unable to travel to or afford to pay for specialized care services. Care for patients suffering from chronic morbidity caused by NID should be integrated into care for other chronic conditions caused by non-communicable diseases. This manual provides a framework for morbidity management and disability prevention of patients affected by NIDs and gives specific guidance for the proper care of patients suffering from chronic conditions caused by lymphatic filariasis, leprosy, trachoma, and Chagas disease. It is intended to be used mainly by health care workers at the primary health care level, but health workers at more complex and specialized levels may also find it useful.

Sign in / Sign up

Export Citation Format

Share Document